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ABSTRACT
ULRICH, JAKE
A systematic investigation of the effects of chain length and ionic
head group on perfluoroalkyl acid binding to human serum albumin. Department
of Chemistry, June 2017
ADVISOR: Laura A. MacManus-Spencer
Perfluoroalkyl acids (PFAAs) are industrial chemicals used in everyday products
ranging from non-stick coatings to fire-fighting foam. PFAAs are contaminants of
emerging concern (CECs) and are bioaccumulative, persistent and toxic. Unlike other
CECs, PFAAs bioaccumulate in areas of high protein concentration, such as the kidneys,
liver and blood; therefore, it is vital to study PFAA-protein interactions. Human Serum
Albumin (HSA) is the model protein used for PFAA-protein studies because it is the most
abundant protein in the human body and it binds and transports endogenous and
exogenous ligands. Previously, researchers have investigated PFAA-HSA binding, but
most of these studies have focused on medium-chain length PFAAs and lacked a
systematic method to quantify PFAA-HSA binding. Additionally, few studies have
focused on determining a relationship between PFAA chain length and binding strength.
In this study, a systematic method was used to determine relationships between PFAA
chain length and ionic head group and protein binding; the binding affinities of short-,
medium- and long-chain PFAAs were determined using a systematic equilibrium dialysis
method coupled with liquid chromatography-tandem mass spectrometry. The results
indicate that the short-chain PFAAs, depending on ionic head group, bind as strongly or
only moderately weaker at the high-affinity sites than the medium- and long-chain
PFAAs.
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Introduction
What are perfluoroalkyl acids?
Perfluoroalkyl acids (PFAAs) are a family of industrial chemicals that are
fluorinated analogs of carboxylic acids. PFAAs are used in a variety of consumer
products, such as non-stick coatings, paper plates, microwave popcorn bags and fire
fighting foams, due to their unique properties of being both hydrophobic and lipophobic,
which causes PFAAs to repel both water and oils. These chemicals have been produced
and used in products since the 1940s. However, in recent years PFAAs have been
classified as Contaminants of Emerging Concern (CECs) because they have been seen to
bioaccumulate in organisms and not degrade in the environment.1-3 These chemicals
accumulate in aquatic environments, sediments and various mammals and organisms;
PFAAs have been detected in trout, rats and the Great Lakes, to name a few.2,4-7
In addition to being bioaccumulative, PFAAs have also been shown to have
adverse health effects. Many of these toxicity studies have been conducted with the
PFAAs perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS).
Studies with PFOA and PFOS in rodents and non-human primates have shown reduced
body weight, liver toxicity and development of cellular tumors.1 Additionally, some
epidemiology studies have seen a correlation between prolonged exposure to PFAAs and
cancer incidence in humans.1 Other toxicity tests have shown that PFAAs could cause
adverse changes in cell membranes and peroxisome proliferation.8 Due to PFAAs being
bioaccumulative, persistent in the environment and exhibiting toxic effects, they have
been designated as PBT (Persistent, Bioaccumulative and Toxic) chemicals by some
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groups. Thus it is important to study PFAAs in order to understand more about their fate
and transport within the environment and in organisms.
Historically, the main PFAAs used in the manufacturing of products have been
perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) and their
derivatives. However, the primary U.S. manufacturers of PFOA and PFOS began to
phase out the production of these chemicals in 2002 (Figure 1) due to reports that these
chemicals bioaccumulate and exhibit toxic effects.1,2,9 These manufacturers have replaced
these longer eight-carbon chemicals with chemicals based on the shorter four-carbon
PFAAs, perfluorobutanoic acid (PFBA) and perfluorobutanesulfonic acid (PFBS).
Therefore, PFAAs are still currently used in the manufacture of everyday products.
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Figure 1. The usage of PFAAs in industry has transitioned over time with companies
switching to chemicals based on the four-carbon PFAAs, PFBS and PFBA, from the
eight-carbon PFAAs, PFOS and PFOA.

Even though the use of longer chain PFAAs has been phased out of by most U.S.
industries, the negative impacts of their bioaccumulation and toxicity are still being seen
today and will be for decades to come. Notably, case after case of drinking water
contamination by PFAAs have recently been revealed. One example that has gained
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national attention is the water crisis in Hoosick Falls, NY. The EPA found that the town’s
drinking water supply was contaminated with PFOA and not potable. The source of the
contamination is thought to be a manufacturing plant most recently operated by SaintGobain Performance Plastics, which had stopped using PFAAs at its main manufacturing
site about 17 years ago. Unfortunately, due to PFAAs being highly persistent within the
environment, the levels of PFOA in the drinking water were found to be above 400 parts
per trillion.10 Additionally, the PFOA levels in the blood of Hoosick Falls residents were
found to be 15 times the national median.11 The toxicological effects of this exposure
have been noticed. In Hoosick Falls, there is an abnormally large incident rate for kidney
cancer, which is one of the cancers associated with PFAA exposure.11 This recent crisis,
among many others, demonstrates just how important it is to study the environmental and
biological fates of PFAAs. Even though the longer chain PFAAs have been phased out of
most U.S. manufacturing, these chemicals are globally pervasive and will continue to
cause problems for decades to come. Additionally, the usage of the less studied short
chain molecules is concerning because they, too, could pose adverse environmental and
human health effects.

Properties of perfluoroalkyl acids
PFAAs are synthetic derivatives of hydrocarbon carboxylates and sulfonates, in
which the hydrogen atoms are replaced with fluorine atoms. There are two synthetic
pathways for converting hydrogenated carboxylates and sulfonates to fluorinated
derivatives. The two pathways developed for commercial production of PFAAs are
electrochemical fluorination and telomerization fluorination.8 The unique hydrophobic
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and lipophobic properties of PFAAs are due to the substitution of the hydrogen atoms for
the fluorine atoms. The general structures for these compounds are shown in Figure 2.
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Figure 2. General structure of perfluoroalkyl carboxylates (PFCAs, left) and sulfonates
(PFSAs, right).
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PFAAs are usually shown as deprotonated due to the low pKa values of the chemicals.
Studies have found that PFAAs have a pKa around 0.5. Due to this low pKa, it is
assumed that PFAAs exist in the environment as the deprotonated carboxylates and
sulfonates.12
As stated earlier, these chemicals have been shown to resist degradation. This
phenomenon can be attributed to the strength of the carbon fluorine bond due to the
immense electronegativity of fluorine. In addition to the hydrophobicity and
lipophobicity of PFFAs, the electronegativity of the fluorine atom allows PFAAs to resist
multiple types degradation such as exposure to strong acids and bases, oxidizing and
reducing agents and many more.13 This resistance to degradation, in part, allows for the
bioaccumulation of these chemicals in organisms. The bioaccumulation and toxicity that
PFAAs have displayed are the reasons why they are highly studied.
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Bioaccumulation and toxicity of perfluoroalkyl acids
The bioaccumulation and toxicity patterns of PFAAs are unlike other hydrophobic
contaminants due to their unique properties. Hydrophobic contaminants tend to
bioaccumulate in fatty tissues while PFAAs mainly bioaccumulate in tissues with high
protein content, such as the blood, liver and kidneys of organisms. PFAAs have been
found to bioaccumulate in organisms ranging from fish to birds to rats to humans.1,9,14-25
The anthropogenic sources of PFAAs have been widely studied in order to better
understand the accumulation of these chemicals in the environment and in humans.
Besides the biomagnification due to exposure from everyday products and consuming
contaminated organisms (mainly fish), the bioaccumulation of theses chemicals can be
attributed to contaminated drinking water supplies, such as in the Hoosick Falls, NY,
case. Recently there have been a few studies examining the sources of PFAAs in drinking
water, and they have determined that the proximity of drinking water resources to
industrial sites, military fire training areas and wastewater treatment plants are all strong
predictors for PFAA water contamination.25-27 Humans and organisms are exposed to
these chemicals in a multitude of ways, and the areas in which they accumulate in the
body are vital for human and organismal health and function. Unfortunately, PFAAs have
been linked to toxicological effects, which is why the areas in which they bioaccumulate
are even more of a concern.
Some of the negative effects that are attributed to PFAAs are adverse changes in
membrane function, mitochondrial bioenergetics and peroxisome proliferation.
Additionally, PFAAs have been linked to numerous toxic effects, such as thyroid cancer,
testicular cancer, liver cancer, neonatal and liver toxicity and tumors in multiple
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organisms.5-7,9 These adverse effects linked to PFAAs are interestingly linked to many of
the areas in which they bioaccumulate. Many of the toxicological effects have been seen
in areas of high protein content, which is why there have been many studies of PFAAprotein interaction. In many of these studies, the model protein used is serum albumin
since it is the most abundant protein found in the blood. One of the main functions of
serum albumin is to transport molecules around the body. Many of these molecules are
fatty acids, which have a similar structure to PFAAs. Serum albumin is also able to
reversibly bind and transport other endogenous and exogenous ligands, which makes it an
ideal model protein to study the fate and transport of PFAAs within the body.28-31

Human serum albumin: the model protein
Human serum albumin (HSA) is the most abundant protein in the human body, at
50 grams per liter. It is produced in the liver and has a half-life of 19 days.32 Some of the
functions of HSA include maintaining blood pH and pressure, transporting fatty acids,
removing oxygen free radicals and its previously mentioned reversible binding
abilitites.32
Due to the ability of HSA to reversibly bind exogenous and endogenous ligands,
it is the model protein used in this study. Many of these endogenous ligands are fatty
acids, which have similar structures to PFAAs. These similarities may suggest that
competitive binding between PFAAs and fatty acids may occur, which means that
PFAAs could interfere with the binding of fatty acids to HSA, and possibly other proteins
as well. HSA consists of a single polypeptide composed of 585 amino acid residues and
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has a molecular weight of approximately 66.5 kDa.28-31 The structure of HSA, acquired
from the protein data bank, can be seen in Figure 3.

Figure 3. Crystal structure of human serum albumin from the protein data bank (ID
1AO6).30
HSA is a good model protein for this study due to it having many sites for binding and
transporting ligands, as well as the fact that it can be found throughout the entire body. It
should be noted that HSA exists as a monomer (a single protein molecule), a dimer (two
proteins), a trimer (three proteins), etc. For this study, a commercially available mix of
HSA was used, meaning HSA existed as a monomer, dimer, trimer, etc. in the mix.
Previous work
Several studies have been conducted to investigate the binding of PFAAs to
serum albumin due to the toxicity and bioaccumulative properties of these chemicals.
However, there are some limitations to the previous studies. One is that most of the
studies primarily focused on the binding of perfluoroctanoic acid (PFOA) and/or
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perfluorooctane sulfonic acid (PFOS) to serum albumin. This is a problem because there
are more than two PFAAs and these two PFAAs are not the ones in production anymore
since they were phased out after 2002.2 Another limitation of previous studies is that
some groups used HSA while others used BSA (bovine serum albumin). If the goal is to
understand the fate and transport of PFAAs in the human body, then HSA should be the
gold standard for PFAA-protein interaction studies.
The typical way to quantify ligand-protein binding is through the dermination of
Ka, the association constant. The Ka values for PFOA-HSA and PFOA-BSA binding from
previous experiments are displayed in Table 1. The Ka values in this table range from 103
to 106 M-1.
Table 1. Magnitudes of literature Ka values for perfluorooctanoic acid
Protein-PFAA System
Ka (M-1)
Source
HSA-PFOA
103
Han et al (2003)33
HSA-PFOA
104
Wu et al (2009)34
4
HSA-PFOA
10
Hebert et al (2010)35
HSA-PFOA
105
Chen et al (20)36
5
HSA-PFOA
10
Messina et al (2005)37
BSA-PFOA
105
MacManus-Spencer et al (2010)38
BSA-PFOA
106
Bischel et al (2010)39
Clearly the vast range of these numbers shows that there is no clear magnitude for how
strongly PFOA binds to HSA. Additionally, these values are only for PFOA, so there is
no systematic understanding of how PFAAs in general bind to HSA. As stated earlier,
PFAAs exist as a variety of chain lengths and with different ionic head groups, and there
has been no definitive relationship determined for how chain length or ionic head group
affects the binding affinity of PFAAs. Lastly, the methods used to study PFAA-HSA
binding have not been ideal. Many of these methods use spectroscopic techniques to
study PFAA-HSA binding, which are indirect methods for determining Ka. However, the
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“gold standard” for protein binding studies is equilibrium dialysis, which is a direct
method. The studies that did use equilibrium dialysis were inconsistent because they
included few PFAA:HSA mole ratios and obtained different data points on different days
due to the tedious nature of equilibrium dialysis. This results in inconsistent and
unreliable Ka values. The focus of this study is to expand upon previous research in the
MacManus-Spencer lab that has focused on quantifying the binding affinities of PFAAs
to HSA using a systematic approach involving a sophisticated, more high-throughput
equilibrium dialysis technique.40-42 The main goal of this study is to determine definitive
relationships between HSA-PFAA binding affinity and PFAA chain length and ionic
head group.

Protein-ligand binding kinetics and binding isotherm plots
Chemical kinetics can be used to characterize the binding interactions between a
protein and a ligand. This can be quantified by determine the binding affinity between a
protein and a ligand via determining the association constant, Ka.
A reversible protein-ligand binding system can be described using the following
equilibrium:
Protein + Ligand ←""""
→ Protein − − − Ligand 	
  
koff
on →
←""
" "k""

The protein and ligand can exist in a bound state as a complex or in an unbound state.
The two rate constants kon (association rate constant) and koff (dissociation rate constant)
govern the state of the protein and ligand. The rate of the forward reaction is proportional
to kon:

Rate = [Protein][Ligand]kon 	
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And the rate of the reverse reaction is proportional to koff:

Rate = [Protein − − − Ligand]koff 	
  
When the system is at equilibrium, the rates of the forward and reverse reactions are
equal; this means that that two rate equations are equal at equilibrium:

[Protein][Ligand]kon =	
   [Protein − − − Ligand]koff 	
  
The association constant, Ka, is defined as the ratio between the association and
dissociation rate constants at equilibrium:

Ka =

kon
	
  
koff

This allows for the rearrangement of the equilibrium expressions to solve for Ka:

[Protein][Ligand]
k
= on = K a 	
  
[Protein − − − Ligand] koff
The Ka value, having units of M-1, is a measure of HSA-PFAA binding affinity. This
means that a larger Ka value indicates stronger binding interactions because a higher
concentration of the HSA-PFAA complex would exist compared to the concentration of
unbound PFAA.
	
  

In order to determine the Ka value for a specific PFAA, a binding isotherm plot is

created. This is done by running an equilibrium dialysis experiment on a 96-well
equilibrium dialyzer plate with a range of PFAA:HSA mole ratios. The amount of free
PFAA is quantified via liquid chromatography – tandem mass spectrometry (LC-MS/MS)
and a binding isotherm plot is created. Plotting the binding coefficient, which is the
concentration of bound PFAA divided by the concentration of HSA, versus the
concentration of free PFAA creates the binding isotherm plot. An example of a
theoretical binding isotherm plot is shown in Figure 4.
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Figure 4. An example of a theoretical binding isotherm plot.
To determine the Ka value for a specific PFAA, nonlinear curve fitting software,
KaleidaGraph, is then used. This software is able to determine the Ka and the binding
stoichiometry (number of PFAAs bound per protein molecule) by fitting the plot with a
binding model. There are several possible binding models that can describe the binding of
PFAAs to HSA; the models used in this study include: one-class binding (equation 1),
two-class binding (equation 2), and one-class that includes a nonspecific binding term
(equation 3). A one class binding model means that PFAAs bind at one type of site on the
protein with similar affinity; a two class binding model means that PFAAs bind at two
types of sites on the protein with different affinities; and a one-class binding model that
includes nonspecific binding means that PFAAs bind at one type of site strongly and then
weakly associate on the surface of the protein.42
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v=

v=

n1K a1[PFAA] free
1+ (K a1[PFAA] free )

1

n1K a1[PFAA] free
n K [PFAA] free
+ 2 a2
1+ (K a1[PFAA] free ) 1+ (K a2 [PFAA] free )

2

n1K a1[PFAA] free
+ K nsb [PFAA] free
1+ (K a1[PFAA] free )

3

v=

Depending on the model fit for each PFAA, certain properties about the bioaccumulation
and transport of that PFAA can be determined, for example, the number of sites to which
it strongly and weakly associates and how strong these interactions are.

Experimental Goals
The main goal of this study is to study PFAA-HSA binding interactions. As stated
earlier, there has been no definitive relationship determined for how PFAA:HSA binding
association strength is affected by PFAA chain length and ionic head group. The first
goal is to determine this relationship using the systematic equilibrium dialysis method
developed in the MacManus-Spencer lab.41,42 This study looks at six different PFAAs
varying in chain length and ionic head group in order to determine a relationship by
quantifying the Ka values for each of these PFAAs to HSA. The PFAAs used in this study
can be seen in Figure 5.
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Figure 5. The six different PFAAs studied to determine the relationships between chain
length and ionic head group and HSA binding constants.
If a relationship between chain length and ionic head group can be established, the fate
and transport of PFAAs in the human body will be more generally understood. Currently,
the fate and transport of PFOA and PFOS is partially understood, but this study will
hopefully allow for the understanding of the fate and transport of all PFAAs. These
results will then hopefully allow for stricter regulation of these chemicals if it is seen that
chain length doesn’t affect the Ka value significantly, meaning the shorter chain PFAAs
bind just as strongly as the longer chain PFAAs.
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Materials
96-well Equilibrium Dialyzer plates and a plate rotator were obtained from
Harvard Apparatus (Holliston, MA). Human serum albumin (HSA; ≥ 99%, essentially
fatty acid and γ-globulin free) was obtained from Sigma-Aldrich (St. Louis, MO), and
66,437 Da was used as the molecular weight.43 Perfluorobutanesulfonic acid potassium
salt (PFBS-K+; 98%), tridecafluorohexane-1-sulfonic acid potassium salt (PFHxS; ≥
98%), perfluorooctanoic acid (PFOA; 96%), perfluorooctanesulfonic acid potassium salt
(PFOS-K+; ≥ 98%) perfluoroundecanoic acid (PFUnA; 95%), and perfluorododecanoic
acid (PFDoA; 95%) were obtained from Sigma-Aldrich. Perfluorobutanoic acid (PFBA;
99%) and perfluorooctanoic acid (PFOA; 96%) were obtained from Acros Organics
(Morris Plains, NJ) through Fisher Scientific USA (Pittsburgh, PA). Sodium phosphate
monobasic (99.3%, monohydrate), sodium phosphate dibasic (99.3%, anhydrous),
ammonium hydroxide (certified ACS Plus), methanol (Optima LC-MS grade, 0.1-micron
filtered), water (Optima LC-MS grade, 0.03-micron filtered), ammonium formate, and
polypropylene microcentrifuge tubes were from Fisher Scientific. Polypropylene
centrifuge tubes (15- and 50-mL) were obtained from Corning Incorporated (Corning,
NY). HPLC autosampler vials and caps were obtained from Kinesis, Inc. (Malta, NY). A
C18 Targa Sprite column (40 x 2.1 mm x 5 µm) was obtained from Higgins Analytical
(Mountain View, CA). Mass labeled [13C4]-PFOA and [13C4]-PFBA (each 50 mg/mL in
methanol) were obtained from Wellington Laboratories, Inc. (Ontario, Canada).
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Methods44
Sample preparation
A pH 7 sodium phosphate buffer was prepared from sodium phosphate monobasic
and sodium phosphate dibasic in Optima LC-MS grade water with a total phosphate
concentration of 50 mM. Stock solutions of all the PFAAs were prepared in either pure
Optima LC-MS grade methanol or a 70:30 mixture of Optima LC-MS grade methanol
and 0.01% ammonium hydroxide in 10 mL volumetric flasks. For the PFAA stock
solutions in 50-mM sodium phosphate buffer (pH 7), PFOA, PFHxS PFBS and PFBA
were prepared in 10-mL volumetric flasks, but due to solubility issues PFDoA and PFOS
were prepared in 100-mL volumetric flasks. If any of the PFAA stock solutions were not
soluble, the solutions were sonicated in a water bath between 35-40°C until dissolved
using a Bransonic Tabletop Ultrasonic Cleaner 3510 (Branson Ultrasonic Corporation;
Danbury, CT). Purity-corrected stock solutions of 500-µM and 50-µM HSA in 50-mM
sodium phosphate buffer (pH 7) were prepared in 50-mL polypropylene centrifuge tubes.
The 500-µM HSA solution was used for the PFBA, PFBS, PFHxS and PFOA
experiments; the 50-µM HSA solutions were used for the PFOS and PFDoA experiments.
This was done to keep the mole ratios of PFAA to HSA (0.01-16) constant from
experiment to experiment. The HSA solution was prepared fresh for every experiment.

Equilibrium dialysis (ED)
Equilibrium dialysis plates from Harvard Apparatus were used to study PFAAHSA binding. The equilibrium dialysis plates contained 96 wells spread out over 12
columns and 8 rows, and the plate was dual-sided. On the protein side (HSA side), 200
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µL of either 500-µM or 50-µM HSA in 50-mM sodium phosphate buffer (pH7) was
pipetted into the amount of wells used for each experiment (usually 57 wells). On the
opposite side, the “ligand” side, 200 µL of a known concentration of PFAA in 50-mM
sodium phosphate buffer (pH 7) was pipetted into the amount of wells used for each
experiment. Furthermore, for each ED experiment run, positive and negative controls
were tested in triplicate. A positive control had 200 µL of a known concentration of
PFAA on the “ligand” side, while on the protein side there was 200 µL of 50-mM sodium
phosphate buffer with no HSA. A negative control had 200 µL of either 500-µM or 50µM HSA in the protein side of the plate, while the PFAA side contained 200 µL of 50mM sodium phosphate buffer. Once the wells were prepared, the plate was secured onto a
plate rotator and rotated at room temperature for 48 hours. Once equilibrated, samples
were collected from the PFAA side of the plate and stored in a cold room (4°C) until
analyzed by LC-MS/MS for free PFAA concentration quantification.

LC-MS/MS quantitative analysis
Samples from the ED experiments were analyzed by LC-MS/MS in order to
determine the concentration of free PFAA, which led to the determination of the Ka for
each PFAA. For each LC-MS/MS vial, 100 µL of sample was pipette in along with 100
µL of 50-mM sodium phosphate buffer and 50 µL of internal standard in Optima LC-MS
grade water, resulting in a total volume of 250 µL. The internal standard used for PFOA
was [13C4]-PFOA, which was used at a final concentration of 50 nM. The internal
standard for PFOS was PFHxS, which was used at a final concentration of 1000 nM. The
internal standard for PFHxS was PFOS, which was used at a final concentration of 1000
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nM. The internal standard used for PFBA was [13C4]-PFBA, which was used at a final
concentration of 10 nM. The internal standard used for PFBS was PFHxS, which was
used at a final concentration of 1000 nM. Lastly, the internal standard used for PFDoA
was PFUnA, which was used at a final concentration of 100 nM. The reason PFDoA,
PFBS and PFOS did not have mass labeled internal standards is that these were not
unknown environmental samples, so it wasn’t necessary to use expensive mass labeled
internal standards since the contents of each sample were known throughout the
experiment.
Sample analysis was done with an Agilent 1200 series HPLC and Agilent 6410B
triple quadrupole mass spectrometer, and the samples were run on a Targa Sprite C18
column from Higgins Analytical. All HPLC separations were isocratic elutions. The
solvents used for LC-MS/MS analysis, with the exception of PFOA, were 2 mM
ammonium formate in either Optima LC-MS grade methanol or Optima LC-MS grade
water. For PFOA, 2 mM ammonium acetate in either Optima LC-MS grade methanol or
Optima LC-MS grade water was used. The PFAAs that were studied using equilibrium
dialysis were PFOA, PFOS, PFHxS, PFBA, PFBS and PFDoA. For each of these six
PFAAs, different isocratic elution conditions were determined for optimal LC-MS/MS
quantification (Table 2).
Table 2. LC-MS/MS solvent conditions used for the various PFAAs
PFAA Analyte
Percent 2 mM Ammonium Percent 2 mM Ammonium
Formate in Methanol
Formate in Water
PFOA*
60%
40%
PFOS
60%
40%
PFHxS
50%
50%
PFBA
10%
90%
PFBS
50%
50%
PFDoA
70%
30%
*For PFOA, 2 mM ammonium acetate was used instead of 2 mM ammonium formate.
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For all methods, a 40-µL injection volume, 0.5 mL/min flow rate and 400 bar maximum
pressure were used as parameters. Additionally, the mass spectrometer was operated in
negative mode for electrospray ionization (ESI) with multiple reaction monitoring
(MRM) analysis. For all analyses a 50 psi nebulizer pressure, 10 L/min gas flow and
350 °C gas temperature were used.
MassHunter optimizer software was used to determine the relevant precursor and
fragment ions for each analyte and internal standard in order to quantify the amount of
free PFAA. Also, the MassHunter optimizer software determined the fragmentor voltages
and collision energies for the MRM methods used for each analyte. The relevant
transition ions monitored, fragmentor voltages and collision energies for each analyte and
internal standard used are shown in Table 3
Table 3. Parameters used for MRM methods in quantification of free PFAA
Analyte
Transition
MRM
Fragmentor
Collision
Type
Transition
Voltage (V)
Energy (V)
(m/z)
PFOA
Quantifier
413 à 369
50
4
Qualifier
413 à 169
50
16
[14C4]-PFOA
Qualifier
417 à 372
50
4
PFOS
Quantifier
499 à 80
180
60
Qualifier
499 à 99
180
56
Qualifier
499 à 298
180
16
PFHxS
Qualifier
399 à 80
150
44
PFHxS
Quantifier
399 à 80
130
52
Qualifier
399 à 90
130
44
PFOS
Qualifier
499 à 80
180
60
PFBA
Quantifier
213 à 169
50
0
13
[ C4]-PFBA
Qualifier
217 à 79
140
48
PFBS
Quantifier
299 à 80
160
36
PFHxS
Qualifier
399 à 80
150
44
PFDoA
Quantifier
613 à 569
70
8
Qualifier
613 à269
70
16
Qualifier
613 à219
70
20
Qualifier
613 à169
70
24
PFUnA
Qualifier
563 à519
60
8
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Additionally, calibration curves were generated for each PFAA in order to quantify the
amount of free PFAA. A calibration curve ranging from 15 nM – 6000 nM was used for
PFOA, while for PFOS, PFBA, PFBS and PFDoA calibration curves ranging from 150
nM – 6000 nM were used. Standards for each of these PFAAs were made within this
concentration range. Stock solutions of known PFAA concentration were prepared in
Optima LC-MS grade methanol with the calibration standards being made according to a
nested dilution scheme in a 70:30 mixture of Optima LC-MS grade methanol and 0.01%
ammonium hydroxide in Optima LC-MS grade water. Each of these standards were
pipetted into an autosampler vial with the respective internal standard and 50-mM sodium
phosphate buffer (pH 7). These standards where then analyzed via LC-MS/MS, and
MassHunter Quantitative Analysis software was used to quantify the concentration of the
standards, produce a calibration curve and utilize the curve to quantify the concentration
of PFAAs from the ED samples.

Human serum albumin binding for perfluorooctanoic acid
In this experiment, seventeen PFOA to HSA mole ratios were tested through
equilibrium dialysis with 500-µM HSA. For each experiment the seventeen
concentrations of PFOA tested were: 5, 25, 100, 250, 400, 600, 800, 1000, 1500, 1800,
2000, 2500, 3000, 3500, 4000, 6000 and 8000 µM. After the 48-hour equilibrium
dialysis, samples were collected from the PFOA side of the plate and then diluted in an
autosampler vial for LC-MS/MS analysis. During LC-MS/MS analysis, the concentration
of free PFOA was determined via the PFOA standards and calibration curve. Once the
free PFOA concentration was determined, the bound PFOA concentration was calculated
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by subtracting the free PFOA concentration from the initial PFOA concentration. The
binding coefficient was determined for each initial PFOA concentration by dividing the
bound PFOA concentration by the concentration of HSA. A binding isotherm plot was
created by plotting the binding coefficients versus the average free PFOA concentration.
Curve fitting software, KaleidaGraph, was then used to determine the binding class
model and binding constant (Ka).
Human serum albumin binding for perfluoroctanesulfonic acid
In this experiment, seventeen PFOS to HSA mole ratios were tested through
equilibrium dialysis with 50-µM HSA. For each experiment the seventeen concentrations
of PFOS tested were: 0.5, 2.5, 10, 25, 40, 60, 80, 100, 150, 180, 200, 250, 300, 350, 400,
600 and 800 µM. After the 48 hour equilibrium dialysis, the same procedure as above
was followed.
Human serum albumin binding for perfluorobutanoic acid
In this experiment, seventeen PFBA to HSA mole ratios were tested through
equilibrium dialysis with 500-µM HSA. For each experiment the nineteen concentrations
of PFBA tested were: 5, 25, 100, 250, 400, 600, 800, 1000, 1500, 1800, 2000, 2500,
3000, 3500, 4000, 6000 and and 8000 µM. After the 48 hour equilibrium dialysis, the
same procedure as PFOA was followed.
Human serum albumin binding of perfluorbutanesulfonic acid
In this experiment, seventeen PFBS to HSA mole ratios were tested through
equilibrium dialysis with 500-µM HSA. For each experiment the seventeen
concentrations of PFBS tested were: 5, 25, 100, 250, 400, 600, 800, 1000, 1500, 1800,
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2000, 2500, 3000, 3500, 4000, 6000 and 8000 µM. After the 48 hour equilibrium
dialysis, the same procedure as PFOA was followed.
Human serum albumin binding for perfluorohexanesulfonic acid
In this experiment, nineteen PFHxS to HSA mole ratios were tested through
equilibrium dialysis with 500-µM HSA. For each experiment the nineteen concentrations
of PFHxS tested were: 5, 25, 100, 250, 400, 600, 800, 1000, 1500, 1800, 2000, 2500,
3000, 3500, 4000, 6000 and 8000 µM. After the 48 hour equilibrium dialysis, the same
procedure as PFOA was followed.
Human serum albumin binding of perfluorododecanoic acid
In this experiment, seventeen PFDoA to HSA mole ratios were tested through
equilibrium dialysis with 50-µM HSA. For each experiment the seventeen concentrations
of PFOS tested were: 0.5, 2.5, 10, 25, 40, 60, 80, 100, 150, 180, 200, 250, 300, 350, 400,
600 and 800 µM. After the 48-hour equilibrium dialysis, the same procedure as PFOA
was followed.
Negative and positive control tests
Negative control tests were conducted (in triplicate) in order to test whether the
experimental conditions had any effect on measured PFAA concentration. In this
experiment, either 500 or 50 µM HSA was pipetted into an equilibrium dialysis well with
50-mM sodium phosphate buffer (pH 7) in the opposite well. After a 48-hour equilibrium
dialysis, samples were collected from the buffer side of the plate and prepared for LCMS/MS analysis. During the LC-MS/MS analysis, it was determined whether any
measurable amount of PFAA could be detected.
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Positive control tests were conducted (in triplicate) in order to test if the PFAAs
were passing through the membrane and not sticking to the walls of the equilibrium
dialysis wells. This was tested by calculating percent recovery values for each PFAA
using the equilibrium dialysis method. In this experiment, 200 µM of each PFAA was
pipette into an equilibrium dialysis well with 50-mM sodium phosphate buffer (pH 7) in
the opposite well. After a 48-hour equilibrium dialysis, samples were collected from the
PFAA side of the plate and then diluted in an autosampler vial for LC-MS/MS analysis.
During LC-MS/MS analysis, the concentration of PFAA was determined via standards
and calibration curves. Once the PFAA concentrations were determined, the sample
dilutions were accounted for to determine the concentration in the PFAA side of the well.
These values were then used to determine the percent recovery values for each PFAA
using the equilibrium dialysis method.

	
  

22

	
  
Results
Perfluorooctanoic acid
The PFOA binding isotherm was generated using the developed equilibrium
dialysis method. The plot was created by plotting the binding coefficients versus the
average free concentrations of PFOA. This was done in previous work by Mike Morris
’14, Andrew Glaser ’16 and replicated in this study. It was determined that PFOA binds
to HSA according to a two-class binding model. It was determined that the Ka1 was 1.1 (±
0.9) × 105 M-1 with n, the approximate number of PFOA molecules binding to that class
of sites (the strong association sites), equaling 1.5 (± 0.9). It was also determined that the
Ka value for the second class of sites (Ka2) was 5.5 (± 0.9) × 103 M-1 with about 14.7 (±
0.6) PFOA molecules binding at that class of sites (the weak association sites). The
binding isotherm for PFOA constructed by Andrew Glaser ’16 is shown in Figure 6.42
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Figure 6. PFOA-HSA two-class binding isotherm determined via equilibrium dialysis by
Andrew Glaser ‘16. This plot was created by plotting the binding coefficients versus the
average free concentrations of PFOA. From this plot the Ka1 was determined to be 1.1 (±
0.9) × 105 M-1 and n1 being 1.5 (± 0.9). Additionally the Ka2 was determined to be 5.5 (±
0.9) × 103 M-1 with n2 being 14.7 (± 0.6).
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Perfluoroocatanesulfonic acid
The PFOS binding isotherm was generated using the developed equilibrium
dialysis method. The plot was created by plotting the binding coefficients versus the
average free concentrations of PFOS. It was determined that PFOS binds to HSA
according to a two-class binding model. The Ka1 value was determined to be 5 (± 4) × 106
M-1 with an n1 value of 1.4 (± 0.4) PFOS molecules binding at the first class of site.
Additionally, the Ka2 was determined to be 9.6 (± 2) × 104 M-1 with an n2 value of 9.6 (±
0.5) PFOS molecules binding at the second class of sites. The binding isotherm
determined for PFOS is shown in Figure 7.
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Figure 7. PFOS-HSA two-class binding isotherm plot determined via equilibrium
dialysis. This plot was created by plotting the binding coefficient versus the average
concentration of PFOS. From this plot the Ka1 was determined to be 5 (± 4) × 106 M-1 and
n1 value of 1.4 (± 0.4). Additionally the Ka2 was determined to be 9.6 (± 2) × 104 M-1 with
an n2 value of 9.6 (± 0.5).
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Perfluorobutanoic acid
The PFBA binding isotherm was generated using the developed equilibrium
dialysis method. The plot was created by plotting the binding coefficients versus the
average free concentrations of PFBA. It was determined that PFBA binds to HSA
according to a two-class binding model. The Ka1 value was determined to be 1.5 (± 0.9) ×
105 M-1 with an n1 value of 1.4 (± 0.3) PFBA molecules binding at the first class of sites.
Additionally, the Ka2 was determined to be 9 (± 1) × 102 M-1 with an n2 value of 11.2 (±
0.5) PFBA molecules binding at the second class of sites. The binding isotherm
determined for PFBA is shown in Figure 8.
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Figure 8. PFBA-HSA two-class binding isotherm plot determined via equilibrium
dialysis. This plot was created by plotting the binding coefficient versus the average
concentration of PFBA. From this plot the Ka1 was determined to be 1.5 (± 0.9) × 105 M-1
and n1 value of 1.4 (± 0.3). Additionally the Ka2 was determined to be 9 (± 1) × 102 M-1
with an n2 value of 11.2 (± 0.5).
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Perfluorobutanesulfonic acid
The PFBS binding isotherm was generated using the developed equilibrium
dialysis method. The plot was created by plotting the binding coefficients versus the
average free concentrations of PFBS. It was determined that PFBS binds to HSA
according to a two-class binding model. The Ka1 value was determined to be 4 (± 1) × 104
M-1 with an n1 value of 2.7 (± 0.3) PFBS molecules binding at the first class of sites.
Additionally, the Ka2 was determined to be 1.8 (± 0.8) × 102 M-1 with an n2 value of 24 (±
7) PFBS molecules binding at the second class of sites. The binding isotherm determined
for PFBS is shown in Figure 9.
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Figure 9. PFBS-HSA two-class binding isotherm plot determined via equilibrium
dialysis. This plot was created by plotting the binding coefficient versus the average
concentration of PFBA. From this plot the Ka1 was determined to be 4 (± 1) × 104 M-1 and
n1 value of 2.7 (± 0.3). Additionally the Ka2 was determined to be 1.8 (± 0.8) × 102 M-1
with an n2 value of 24 (± 7).
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Perfluorohexanesulfonic acid
The PFHxS binding isotherm was generated using the developed equilibrium
dialysis method. The plot was created by plotting the binding coefficients versus the
average free concentrations of PFHxS. It was determined that PFHxS binds to HSA
according to a two-class binding model. The Ka1 value was determined to be 1.6 (± .7) ×
105 M-1 with an n1 value of 2.5 (± 0.5) PFHxS molecules binding at the first class of sites.
Additionally, the Ka2 was determined to be 2.0 (± 0.6) × 103 M-1 with an n2 value of 24 (±
3) PFHxS molecules binding at the second class of sites. The binding isotherm
determined for PFHxS is shown in Figure 9.
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Figure 10. PFHxS-HSA two-class binding isotherm plot determined via equilibrium
dialysis. This plot was created by plotting the binding coefficient versus the average
concentration of PFBA. From this plot the Ka1 was determined to be 1.6 (± 0.7) × 105 M-1
and n1 value of 2.5 (± 0.5). Additionally the Ka2 was determined to be 2.0 (± 0.6) × 103
M-1 with an n2 value of 24 (± 3).
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Perfluorododecanoic acid
The PFDoA binding isotherm was generated using the developed equilibrium
dialysis method. The plot was created by plotting the binding coefficients versus the
average free concentrations of PFDoA. It was determined that PFDoA binds to HSA
according to a two-class binding model. The Ka1 value was determined to be 1.3 (± 0.8) ×
106 M-1 with an n1 value of 3.0 (± 0.96) PFDoA molecules binding at the first class of
sites. Additionally, the Ka2 was determined to be 2.9 (± 0.97) × 104 M-1 with an n2 value
of 13.8 (± 0.9) PFDoA molecules binding at the second class of sites. The binding
isotherm plot determined for PFDoA is shown in Figure 10.
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Figure 11. PFDoA-HSA two-class binding isotherm plot determined via equilibrium
dialysis. This plot was created by plotting the binding coefficient versus the average
concentration of PFDoA. From this plot the Ka1 was determined to be 1.3 (± 0.8) × 106
M-1 and n1 value of 3.0 (± 0.96). Additionally the Ka2 was determined to be 2.9 (± 0.97) ×
104 M-1 with an n2 value of 13.8 (± 0.9).
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Summary of binding isotherm results
Since each PFAA exhibited a two-class binding model, it allows for the
comparison of all of the values derived from the binding isotherm plots. The Ka1, n1, Ka2
and n2 values for each PFAA are shown in Table 4.
Table 4. Summary of the Ka and n values derived
binding model
PFAA
Ka1 (M-1)
n1 (sites)
PFBA
1.5 (± 0.9) x 105
1.4 (± 0.3)
PFOA
1.1 (± 0.9) x 105
1.5 (± 0.9)
6
PFDoA
1.3 (± 0.8) x 10
3 (± 0.96)
PFBS
4.0 (± 1.0) x 104
2.7 (± 0.3)
PFHxS
1.6 (± 0.7) x 105
2.5 (± 0.5)
PFOS
5.0 (± 4.0) x 106
1.4 (± 0.4)

	
  

for each PFAA using the two-class
Ka2 (M-1)
9.0 (± 1.0) x 102
5.5 (± 0.9) x 103
2.9 (± 0.97) x 104
1.8 (± 0.8) x 102
2.0 (± 0.6) x 103
9.6 (± 2.0) x 104

n2 (sites)
11.2 (± 0.5)
14.7 (± 0.6)
13.8 (± 0.9)
24.0 (± 7.0)
24.0 (± 3.0)
9.6 (± 0.5)
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Since each PFAA displayed a two-class binding model, each type of Ka value
could be compared to see if a relationship between association strength and chain length
and ionic head group could be determined. The Ka1 and Ka2 values for the carboxylates
and

	
  

sulfonates
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and

13,

respectively.
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Figure 12. Bar graph displaying the Ka1 values for the six PFAAs tested in this study. A
distinct relationship can be seen for the Ka1 values between increasing chain length and
increasing association strength amongst the sulfonates, while the carboxylates do not
display this relationship. The replacement carboxylate, PFBA, seems to associate just as
strongly as the previously used carboxylate, PFOA. Different letters denote statistically
significant differences among Ka1 values (p < 0.05).
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Figure 13. Bar graph displaying the Ka2 values for the six PFAAs tested in this study. A
distinct relationship between increasing chain length and increasing association strength
can be seen for the Ka2 values amongst both the carboxylates and sulfonates used in this
study. Different letters denote statistically significant differences among Ka2 values (p <
0.05).
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Negative and positive control results
Equilibrium dialysis samples containing no added PFAAs were run as negative
controls through the full equilibrium dialysis experiment. No PFAAs were detected in
any of the negative control tests. Positive control equilibrium dialysis samples containing
a concentration of 200 µM for PFBA, PFBS, PFHxS and PFOA, and 20 µM for PFOS
and PFDoA were run through the method. The measured concentrations and percent
recoveries for each PFAA can be seen in Table 5.
Table 5. Concentrations and percent recoveries for each PFAA from the positive control
tests
PFBA
PFOA
PFDoA
PFBS
PFHxS
PFOS
Concentration (µM) 207.6
196.6
2.03
211.18
195.3
12.58
Percent Recovery
104%
98%
10%*
106%
98%
63%*
*These PFAAs will be run through a positive control test again.
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Discussion
Understanding the strong and weak association strengths of the various PFAAs
All the PFAAs tested in this study associate to HSA according to a two-class
binding model, meaning there are two types of sites at which PFAAs bind to HSA with
different affinities (Ka1 and Ka2) and numbers of PFAA molecules (n1 and n2).42 The two
types of sites may be classified as high-affinity binding sites (Ka1 and n1) and loweraffinity binding sites (Ka2 and n2). The n1 values for the 6 PFAAs range from ~1-3, which
means that ~1-3 PFAA molecules bind at the high-affinity site(s) on HSA. For the loweraffinity site(s), many more PFAAs bind demonstrated by the n2 values ranging from ~1024 PFAA molecules at the lower-affinity site. The n1 values demonstrated here agree with
the crystal structure of PFOS bound to HSA. Previous work has shown that
approximately 2 PFOS molecules bind to HSA with high-affinity,45 which agrees with
what was seen for all PFAAs.
As each PFAA binds to HSA according to a two-class binding model,
comparisons of both Ka values can be done to see if a relationship between association
strength and PFAA chain length and ionic head group exists. It should also be noted that
only Ka1 values are available in the literature, and the values derived in this experiment
agree with the higher reported Ka1 values. These discrepancies can be attributed to the
other studies either using spectroscopic binding studies (which are indirect methods and
not the gold standard for protein binding studies) or due to the fact that many of these
studies had limited data points to the inconsistencies in the equilibrium dialysis methods
used. Both of these factors make it hard to compare the calculated Ka1 values to any
previously determined values.
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There is a clear relationship between increasing chain length and increasing
association strength at the high-affinity sites (Ka1) for the PFSAs (Figure 12). For the
PFCAs, this relationship is not as distinct (Figure 12). PFBA and PFOA display similar
Ka1 values while PFDoA has a larger Ka1 value, demonstrating that the same relationship
between increasing chain length and increasing association strength as seen for the
PFSAs does not exist at the high-affinity sites for the PFCAs. For the lower-affinity sites,
there is a clear relationship between increasing chain length and increasing association
strength for both PFCAs and PFSAs (Figure 13). As the PFAA chain length increases for
both ionic head groups, the association strength increases as well, though all of the Ka2
values are significantly lower than the Ka1 values.
The observed relationship of increasing chain length and increasing association
strength amongst PFSAs can be related to the hydrophobicity of the chemicals. Previous
work has shown that the soil adsorption strength of PFAAs increases with increasing
hydrophobicity.46 Additionally, previous work with PFOA and PFDA (perfluorodecanoic
acid) has shown that increasing hydrophobicity was a major contributor to increasing
association strength to BSA.47 This previous work supports some of the data presented in
here and help to explain some of the observed relationships, specifically for the PFSAs.
For the PFCAs, a systematic relationship between chain length and association strength
was only observed at the lower-affinity sites. This relationship may also be explained by
the increasing hydrophobicity of the longer chain PFAA molecules.
However, the systematic relationship between chain length and association
strength is not observed for the PFCAs at the high-affinity sites. PFDoA does have a
stronger association constant when compared to PFOA, which is comparable to previous
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studies,47 but PFBA associates just a strongly as PFOA. This result is comparable to
previous Ka1 data derived for PFBA. Bischel et al. found that PFBA and PFPnA
(perfluoropentanoic acid, another short chain PFAA) had high association constants when
binding to BSA,48 which were comparable to the association constants derived for PFOA
in an earlier paper.39 This can possibly be explained by the size and rigidity of PFBA
compared to PFOA. PFBA is a smaller molecule, possibly allowing it to more easily fit
into binding pockets of HSA, resulting in the apparent comparable Ka1 values. Previous
work has shown that the size and shape of PFAAs affect association strengths, showing
that branched isomers of PFAAs have weaker association strengths than the linear
PFAAs.49 Additionally, previous work with fluorinated compounds has found that
fluorinated molecules are extremely rigid in nature, but longer fluorinated molecules are
more rigid then shorter fluorinated molecules.50 PFBA is a much shorter chain PFAA
than PFOA, meaning that it may be less rigid, and this lack of rigidity may cause the
apparent comparable Ka1 value. To compare to another short chain PFAA, PFBS has a
slightly lower Ka1 than PFBA and PFOA. It is both less hydrophobic than PFOA, but
more rigid and larger than PFBA. This can help to explain how rigidity, size and
hydrophobicity of PFAAs play a role in PFAA-HSA association at the high-affinity sites.
The results presented here can potentially provide insight into what factors affect
the strength of association of PFAAs at each of the types of association sites on HSA.
Due to the distinct relationship between chain length and association strength displayed
for both the PFCAs and PFSAs at the lower-affinity sites, hydrophobicity seems to be the
main factor affecting association at this site. Due to the differences seen in the association
strengths for the various PFAAs at the high-affinity sites, other factors besides
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hydrophobicity seem to be affecting association strengths. Based on what is known about
fluorinated chemicals, it seems that size, rigidity and hydrophobicity are affecting the
association strengths at the high-affinity sites on HSA.

Evaluating the association strengths of the replacement PFAAs
There is a general lack of sufficient data on the association of PFBA and PFBS to
HSA, which is concerning since these are two of the replacement PFAA chemicals used
in industry. Here we present new data on the high-affinity association of the short-chain
PFAAs to HSA, as well as the first data on the lower-affinity association of these
chemicals. Understanding the association constants for both of these PFAAs allows for
their evaluation as replacement chemicals in the manufacture of everyday products, such
as non-stick pans and oil- and water-repellant clothing. The Ka1 values presented here for
PFBA and PFBS are slightly lower than those previously reported for short-chain PFAAs
in one previous equilibrium dialysis study.48 However, the lack of data points and smaller
range of PFAA:HSA mole ratios tested (and, therefore, much larger errors) in the
previous study make it difficult to compare to the Ka1 values derived here. Additionally,
the previously reported Ka1 values were determined using BSA as the model protein
instead of HSA, also limiting our ability to make comparisons to prior data.
The magnitudes of the Ka1 values for these chemicals allows for the determination
of whether or not PFBA and PFBS are smart choices as replacement chemicals. The Ka1
values are more important for understanding whether or not these chemicals are good
replacements because these values represent high-affinity association to HSA and most
likely represent how PFAAs are transported in the human body. PFBA binds to HSA
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with a Ka1 of 1.5 (± 0.9) x 105 M-1, which is similar to the high-affinity association
strength of PFOA (1.1 (± 0.9) x 105 M-1), which is the chemical PFBA replaced.
Therefore, PFBA may not be a suitable replacement for PFOA. PFBS binds to HSA with
a Ka1 of 4.0 (± 1.0) x 104 M-1, which is weaker than the high-affinity association strength
of PFOS (5.0 (± 4.0) x 106 M-1), the chemical that PFBS replaced. However, PFBS binds
only moderately weaker to HSA than PFOA, which calls into question whether PFBS is a
suitable PFAA replacement chemical to use. Additionally, since both of these
replacement chemicals do bind to HSA, they still have the potential to bioaccumulate in
the body and could potentially display adverse effects.

Evaluation of the negative and positive control tests
The negative control tests were conducted to see if the developed method was
subject to any background PFAA signals. The test resulted in each PFAA having a
concentration of 0 µM, which means is accurately reporting the free PFAA concentration.
This means that the measured concentrations for the various PFAAs evaluated using this
method are due to the amount of PFAA left over in the equilibrium dialysis well and are
not influenced by other factors in the method.
The positive control tests were conducted to ensure that the measured free
concentrations of PFAAs at equilibrium were representative and not affected by the
possible binding of the PFAAs to the walls of the equilibrium dialysis plates. In order to
validate the method, a goal percent recovery of 80-120% was established for each PFAA.
PFBA, PFOA, PFHxS and PFBS resulted in percent recoveries of 104%, 98%, 98% and
106%, respectively. These results mean that these PFAAs are traveling through the
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membrane and coming to equilibrium with the other well and are not adhering to the
walls of the plates. PFDoA and PFOS resulted in percent recoveries of 10% and 63%,
which is not ideal. These 2 chemicals will be run again to ensure that all 6 of the PFAAs
are traveling through the membrane.

Conclusions
In this study, the factors affecting the association of PFAAs to HSA at two
different classes of sites were observed. Due to the chain length dependent relationship
displayed at the lower-affinity sites, it seems that hydrophobicity plays a major role in
association at those sites, with the longer and more hydrophobic PFAAs having higher
association constants. At the high-affinity sites, it seems that additional factors affect the
association of each PFAA. The association strengths of the PFSAs display the same chain
length dependence, while those for the PFCAs do not. Due to PFBA having a higher than
expected association constant when looking at hydrophobicity alone, it seems that factors
such as rigidity, shape and size play a role in the strength of association at these sites.
Additionally, based on the strength of the observed Ka1 values of PFBA and PFBS, these
chemicals may not be suitable replacements, especially PFBA since it associates just as
strongly as PFOA at the high-affinity sites. Lastly, this is the first study to use a highthroughput method to systematically investigate the effects of chain length and ionic head
group on PFAA-HSA binding, and the data gathered here represent the type of data that
are needed for additional replacement chemicals and other poly- and perfluoroalkyl
substances that are still in use.
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Future Work
Immediate future work involves positive control tests will be run with PFDoA and
PFOS, to determine if these chemicals travel across the equilibrium dialysis membrane.
These are vital in testing the validity of the developed method. Additionally, future work
involves studying the binding of PFAAs under varying conditions such as pH,
temperature and ionic strength in order to test the affects of these variables on association
strength. Long-term goals involve exploring PFAA-HSA binding through competitive
binding studies in order to test whether the presence of fatty acids inhibits the binding of
PFAAs to HSA.
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Appendix
Sample chromatograms of PFAAs

Figure 14. Sample chromatogram of PFBA with internal standard mPFBA. The peaks on
the left are mPFBA with the peak on the right being PFBA.
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Figure 15. Sample chromatogram of PFOA with internal standard mPFOA. Both elute at
similar times resulting in a singular peak.
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Figure 16. Sample chromatogram of PFDoA with PFUnA as the internal standard.
PFUnA is the peak on the left and PFDoA is the peak on the right.
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Figure 17. Sample chromatogram of PFBS with PFHxS as the internal standard. PFBS is
the peak on the left and PFHxS is the peak on the right.
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Figure 18. Sample chromatogram of PFHxS with PFOS as the internal standard. PFHxS
is the peak on the left and PFOS is the group of peaks on the right.
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Figure 19. Sample chromatogram of PFOS with PFHxS as the internal standard. PFHxS
is the peak on the left and PFOS is the group of peaks on the right.
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Sample calibration curves for PFAAs

Figure 20. Sample calibration curve used to quantify the concentration of free PFBA post
equilibrium dialysis. The fit is quadratic and has an R2 of 0.9989.
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Figure 21. Sample calibration curve used to quantify the concentration of free PFOA
post equilibrium dialysis. The fit is linear and has an R2 of 0.9986.
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Figure 22. Sample calibration curve used to quantify the concentration of free PFDoA
post equilibrium dialysis. The fit is quadratic and has an R2 of 0.995.
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Figure 23. Sample calibration curve used to quantify the concentration of free PFBS post
equilibrium dialysis. The fit is quadratic and has an R2 of 0.9929.
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Figure 24. Sample calibration curve used to quantify the concentration of free PFHxS
post equilibrium dialysis. The fit is quadratic and has an R2 of 0.9973.
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Figure 25. Sample calibration curve used to quantify the concentration of free PFOS post
equilibrium dialysis. The fit is quadratic and has an R2 of 0.9981.
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